WO2001029244A1 - Transporteur d'acide nucleique contenant un polypeptide et un vecteur viral de recombinaison - Google Patents
Transporteur d'acide nucleique contenant un polypeptide et un vecteur viral de recombinaison Download PDFInfo
- Publication number
- WO2001029244A1 WO2001029244A1 PCT/JP2000/007337 JP0007337W WO0129244A1 WO 2001029244 A1 WO2001029244 A1 WO 2001029244A1 JP 0007337 W JP0007337 W JP 0007337W WO 0129244 A1 WO0129244 A1 WO 0129244A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- nucleic acid
- vector
- present
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Definitions
- Nucleic acid carriers containing polypeptides and recombinant viral vectors are provided.
- the present invention relates to a nucleic acid carrier containing a recombinant virus vector for use in gene therapy.
- a treatment method targeting blood cells a treatment method (US Pat. No. 5,399,346) is used in which target blood cells are once separated from a living body, transfected in a test tube, and then returned to the living body (US Pat. No. 5,399,346).
- Gene Transfer Law the gene transfer efficiency is low (Dunbar, CE, et al., Blood 85, 3048-3057, 1995), and multiple gene transfer operations are required. Remains.
- both polyprene and polyethyleneimine are substances that do not exist in living organisms, so that administration to living organisms is difficult.
- cationic ribosomes have high toxicity depending on the composition of ribosomes prepared (Yagi K. et al., Biochem. Biophys. Res. Co. un. 196, 1042- 1048, 1993) Attention is required.
- synthetic polyamino acids, especially polylysine tend to precipitate with increasing concentration, and are, in fact, difficult to use for treating diseases.
- administration of a drug solution containing particles that cause precipitation into the vein may cause embolization or thrombosis of blood vessels, and may cause clogging of injection needles even when administered locally.
- problems such as the inability to introduce a gene in an amount necessary for treating target cells.
- An object of the present invention is to provide a nucleic acid carrier for efficiently and safely introducing a drug gene into cells.
- the present inventors have made intensive studies to solve the above problems, and as a result, using a nucleic acid carrier comprising a polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof and a recombinant virus vector
- the present inventors have found that drug genes can be efficiently and safely introduced into cells, and have completed the present invention.
- the present invention relates to diaminobutyric acid and Z or a pharmaceutically acceptable salt thereof. And a nucleic acid carrier comprising a recombinant viral vector.
- the present invention also provides the nucleic acid carrier, wherein the polypeptide comprises a block copolymer of a polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof and polyethylene glycol.
- the present invention provides the nucleic acid carrier, wherein the polypeptide comprises diaminobutyric acid having a residue number of 20 to 280 and / or a pharmaceutically acceptable salt thereof. I do.
- the present invention provides any one of the above nucleic acid carriers, wherein the recombinant virus vector contains a drug gene.
- the present invention provides any one of the above nucleic acid carriers, wherein the recombinant virus vector is an HIV vector.
- the present invention provides the above nucleic acid carrier, wherein the HIV vector is a pseudotype HIV vector with VSV-G.
- an agent for improving the gene transfer efficiency of a recombinant virus vector which comprises a polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof as an active ingredient.
- FIG. 1 is a diagram showing an example of a synthesis route of diaminobutyric acid and a pharmaceutically acceptable salt thereof according to the present invention.
- FIG. 2 is a schematic diagram showing the structure of helper plasmid PCMV-R8.2, which constitutes the recombinant virus vector according to the present invention.
- FIG. 3 is a schematic diagram showing the structure of a plasmid pMD.G for supplying VSV-G, which constitutes the recombinant virus vector according to the present invention.
- FIG. 4 is a schematic diagram showing the structure of the vector plasmid pHXCAGEGFP constituting the recombinant virus vector according to the present invention.
- FIG. 5 is a diagram showing the H results of EGFP gene transfer + by the GFP / HIV vector-1 / PDBA complex, which is the nucleic acid carrier of the present invention.
- FIG. 6 shows the stability of the nucleic acid carrier of the present invention, GFP / HIV vector-1 / PDBA complex.
- the polypeptide comprising diaminobutyric acid according to the present invention has a structure represented by the formula (1) (where n represents a natural number), and may optionally contain other monomer units. Good.
- the polypeptide comprising a pharmaceutically acceptable salt of diaminobutyric acid according to the present invention has a structure represented by the formula (2) (where n represents a natural number): Optionally, other monomer units may be included.
- polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof may have a structure containing the above two structures in any ratio. That is, those which exist in any ratio in the form of polydiaminobutyric acid or a pharmaceutically acceptable salt thereof are also included.
- the diaminobutyric acid is an optical isomer!
- the diaminobutyric acid and z or a pharmaceutically acceptable salt thereof according to the present invention may be in the D-form or the L-form, or a mixture thereof arbitrarily. It also includes peptides. That is, any polypeptide containing any of poly-L-diaminobutyric acid, poly-D-diaminobutyric acid, and poly-DL-diaminobutyric acid may be used.
- the term “residue of a polypeptide comprising diaminobutyric acid and Z or a pharmaceutically acceptable salt thereof” refers to diaminobutyric acid, which is a monomer forming the polypeptide (or a pharmaceutically acceptable salt thereof).
- the number of residues thereof means the number of those molecules (ie, represented by n in the above formula).
- the preferred number of residues of the polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof according to the present invention is at least 10 or more. It is more preferably at least 20 residues or more, most preferably 25 or more residues.
- the preferred number of residues of the polypeptide comprising diaminobutyric acid and Z or a pharmaceutically acceptable salt thereof according to the present invention is preferably 280 or less. More preferably, the number is 250 or less. If the number of residues is too large, synthesis becomes difficult and handling becomes inconvenient. On the other hand, if the number of residues is too small, the performance as a nucleic acid carrier will be insufficient.
- the preferred number of residues can be optimally selected depending on the type of the recombinant virus vector to be used and the properties of components that can be used simultaneously.
- the pharmaceutically acceptable salt of diaminobutyric acid is not particularly limited as long as it does not show toxicity or shows an acceptable degree of toxicity when the nucleic acid carrier of the present invention is administered to a subject.
- an inorganic acid salt such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, citric acid, lactic acid, oxalic acid, succinic acid, tartaric acid, malonic acid, fumaric acid
- Organic acid salts such as vac acid and malic acid are mentioned, and among these, acetate is particularly preferable.
- polypeptide of diaminobutyric acid and / or a pharmaceutically acceptable salt thereof is a diaminobutyric acid'acetate
- the diaminobutyric acid'acetate has a molecular weight of 160, and the above-mentioned residue is used. It is also possible to represent the numbers by molecular weight.
- Another example of a polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof according to the present invention (hereinafter also referred to as “polypeptide according to the present invention”) is a polypeptide comprising diaminobutyric acid described above.
- Peptides include those having a block copolymer structure in which polyethylene glycol is further bound, and are represented by Formula (3) (where m and n each represent a natural number).
- the polypeptide has one carboxylic acid group
- the one having the above-mentioned block copolymer structure may be represented by the formula (4) (where m , N, n 'indicate natural numbers respectively).
- the molecular weight (or several m) of ethylene glycol is not particularly limited, but is usually preferably about 200 to 25,000 for the reasons described later.
- a tissue-specific ligand can be bound to the polypeptide of the present invention.
- the nucleic acid carrier of the present invention containing such a polypeptide is effectively and tissue-specifically incorporated into a specific tissue to which the ligand is specific.
- saccharides galactose, lactose, sialoglycoprotein, oligogalactose, hyaluronic acid, etc.
- the nucleic acid carrier of the present invention can be more effectively delivered to the liver.
- diaminobutyric acid represented by the formula (3) or (4) is used as the polypeptide of the present invention.
- PEG polyethylene glycol
- the molecular weight of PEG is preferably not more than 2,500, more preferably not more than 10,000, and most preferably not more than 5,000. Above 5,000, the efficiency of nucleic acid (gene) transfer decreases due to a decrease in affinity with the cell surface, and below 2,000, the effect of the target PEG is small, which is not preferred.
- the method for synthesizing the polypeptide according to the present invention is not particularly limited.
- Organic chemical reactions including various commonly known methods for synthesizing polypeptides can be preferably used.
- the monomer component is obtained by polymerization by an appropriate reaction.
- the monomers used are diaminobutyric acid, Diaminobutyric acid in which a protecting group is introduced into a amino group, or diaminobutyric acid having an amino group and / or a carboxylic acid group activated for peptide group formation can be preferably used.
- amine compounds and alcohol compounds can be used.
- examples of the amine compound include alkylamines, and butylamine is particularly preferable.
- polyethylene glycols are used as alcohols, a polypeptide according to the present invention to which a polyethylene glycol group is added (that is, consisting of a block copolymer of diaminobutyric acid and polyethylene glycol) can be obtained.
- FIG. 1 illustrates a particularly preferred synthetic route for the synthesis of the polypeptide according to the present invention. That is, it is preferable to protect the amino group with an appropriate protecting group and convert the amino acid portion into an acid anhydride using phosgene, and use it as a condensation polymerization monomer ((10) in FIG. 1). Also, by using this monomer, an appropriate initiator can be used in the polycondensation reaction, and a preferable number of monomers can be introduced. Although there is no particular limitation on the initiator, various amine compounds are preferred, and butylamine is particularly preferred. Also, by using an appropriate ethylene glycol as an initiator, it is also possible to obtain a block copolymer having a preferred number of monomers and having an ethylene glycol group. . Specifically, according to the method described in Helv. Chim. Acta, 43, 270-279 (1960) or “New Experimental Chemistry Course 19 Polymer Chemistry ⁇ 1980, published by Maruzen Co., Ltd.” It can be carried out.
- the structure of the polypeptide according to the present invention has the characteristics described above. It is. Therefore, it is possible to detect the polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof according to the present invention based on such structural characteristics. In addition, even when the polypeptide of the present invention itself, or a nucleic acid carrier or a composition for gene therapy using the same is used in various forms of use, it is possible to carry out an appropriate pretreatment. Similarly, the polypeptide according to the present invention can be detected. It is easy for those skilled in the art to select the necessary pretreatment.
- the detection method is not particularly limited, and various generally known polypeptide analysis methods (Young HC, et al., J.
- Controlled Release 54, 39-48, 1998) can be used.
- qualitative and quantitative analysis of diaminobutyric acid by amino acid analysis of peptides determination of the number of residues by molecular weight measurement using various liquid chromatographs, various spectrum analysis to detect the presence of polyethylene glycol groups ( Infrared absorption spectrum, nuclear magnetic resonance absorption spectrum), mass spectrometry, or chemical qualitative analysis methods can be used.
- the recombinant virus vector according to the present invention can be produced based on DNA or RM virus, but the virus species from which it is derived is not particularly limited, and it includes MoMLV vector, Herpes virus vector, Any virus vector such as an adenovirus vector, an MV vector, an HIV vector, or a Sendai virus vector may be used. Furthermore, a virus having a host range other than human can be used as a virus vector if the virus has a therapeutic effect.
- an HIV vector is particularly preferably used. Since the HIV vector integrates the introduced nucleic acid into the chromosome, the drug gene, which is the nucleic acid, can be expressed over a long period of time. In addition, the HIV vector can selectively transfer genes to CD4 positive T cells, which are cell surface molecules. Furthermore, since the HIV vector can be integrated into the chromosome even in the quiescent phase when the cell is not dividing, using the pseudotyped HIV virus vector described below It is possible to efficiently introduce a drug gene into any cell in the stationary phase, such as stem cells, hematopoietic stem cells, nerve cells, and muscle cells.
- a virus vector can also be used as the recombinant virus vector according to the present invention.
- VSV Vesicular stomatitis virus
- a gene group containing the HIV gag poU env gene and lacking a packaging signal was prepared, and a gene construct in which a cytomegalovirus (CMV) promoter was located upstream of the gene construct was used as a replication origin for the ampicillin resistance gene and SV40.
- the helper plasmid (pCMV-R9) inserted into the expression vector containing is constructed by a known gene manipulation method.
- pCMV-R9 inserted into the expression vector containing is constructed by a known gene manipulation method.
- a part of the env gene of PCMV-H9 is deleted, and PCMV-R8.2 that does not express the Env protein is constructed by a known gene manipulation method.
- the above genes can be constructed based on the genome sequences of immunodeficiency virus in mammals, including HIV-1 HIV-2 and simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), etc. .
- Co-transfection of helper plasmid and plasmid pMD.G that expresses VSV-G protein into cells as shown below, allows pseudotyped recombination using VSV-G as a coat protein by cotransfection into cells. HIV virus vectors can be prepared.
- the RCR By removing the packaging signal from the helper plasmid, the RCR
- any one or more of the vif, vpr, vpu, tat, rev, nef genes other than the gag, pol, and env genes required to constitute HIV, or one or more of the accessory genes corresponding thereto are arbitrarily deleted.
- the promoter used to express the HIV gene is not limited to CMV.For example, use a promoter such as CAG, RSV, TK, SV40, SR-hi,? -Actin, EF1-hi, etc. Can o
- an enhancer sequence that enhances the promoter is added by a viral enhancer protein such as herpes virus or hepatitis B virus, or a cellular transcriptional activator protein such as NF_B or SP-1.
- the plasmids encoding these proteins can be cotransfected to produce recombinant HIV vectors.
- the cells for preparing the recombinant HIV vector can be any cell line that can produce the HIV protein.
- mammalian cell lines such as CV-1, HeLa, Raji, RD, SW480, CH0, COS, 293 cells, 293T cells transformed with SV40 large T antigen, and particularly C0S, 293T cells are preferred, and more preferably 293T cells.
- HIV-LTR Long-Terminal-Repeats: consisting of U3, R, U5 regions
- packaging signal any promoter that expresses drug gene, drug gene and HIV-LTR.
- a vector plasmid in which the gene construct in which these are arranged is inserted into an expression plasmid containing an ampicillin resistance gene and a replication origin of SV40 is constructed by a known gene manipulation method.
- the vector is HIV-1, HIV-2, simian immunodeficiency virus (SIV), cat It can be constructed based on the genome sequence of immunodeficiency virus in mammals, including immunodeficiency virus (FIV).
- a polyadenylation signal sequence can be added to the drug gene as needed.
- any promoter that expresses a drug gene For example, promoters such as CAG, CMV, RSV, TK, SV40, SR-hi, MBP,? -Actin, and EF tohi are used. be able to.
- the LTR at the end of the drug gene and the promoter that expresses it, and the LTR at the end use the U3 region of the LTR as a promoter such as CAG, CMV, RSV, TK, SV40, SR-H, MBP, actin, and EF1-H.
- a substituted, chimeric LTR can be used.
- the plasmid thus constructed is cotransfected into, for example, COS cells by a known method such as a calcium phosphate method, a lipofection method using various cationic lipids, or an electoporation method.
- the infected cells are cultured for 24 to 72 hours at the optimal temperature for the host cell used, but more preferably for at least 48 hours or more.
- the recombinant HIV vector released into the culture supernatant is derived from the host cells by centrifuging the culture supernatant at 2000 rpm for 10 minutes or using a filter with a pore size of 0.45 zm. By removing the contaminants, a recombinant HIV vector solution can be prepared. Further, impurities can be removed by a density gradient centrifugation method, PEG (Polyethylene glycol) precipitation method, or a column method such as a cellulose sulfate column or an affinity column.
- PEG Polyethylene glycol
- the drug gene and other genes to be inserted into the recombinant virus vector according to the present invention are composed of various nucleic acids and derivatives of Z or nucleotide, and their type, molecular weight, shape, sequence and the like are not particularly limited.
- nucleic acids have the form of a single-stranded gene, a double-stranded gene, a triple RNA, DNA / RNA chimeric gene, phosphorothioate gene, linear gene, circular gene and the like can be used without limitation.
- sequence of the gene encoded in the recombinant virus vector may be a drug gene, a promoter for transcription of the drug gene, a poly-A signal, a label of a cell into which the gene has been introduced.
- a signal sequence for retention etc., but any sequence can be used.
- a gene corresponding to the disease that is, a gene that acts antagonistically to the disease or a gene that complements the lack in the disease is used.
- genes for specific diseases include SOD, anti-inflammatory cytokines, genes encoding peptides that act antagonistically to cell adhesion factors, and enzyme deficiency for inflammatory diseases.
- Genes encoding normal enzymes, genes encoding normal receptors for receptor deficiency, thymidine kinase, diphtheria toxin, etc. for killing virus-infected cells for viral infections Genes encoding antisense, triple helix, ribozyme, decoy, transdominant mutant, etc., which inhibit the replication of genes and viruses encoding toxins, thymidine kinase for killing cancer cells, and diphtheria for cancer.
- Antisense for inactivating genes encoding toxins and other toxins and oncogenes Genes encoding ribozyme, triple helix, etc., tumor suppressor genes such as p53 for normalizing cancer cells, antisense, triple helix for inactivating genes involved in multidrug resistance to anticancer drugs And genes encoding ribozyme, and for familial hypercholesterolemia, genes encoding the LDL receptor.
- any expression cassette used for the drug gene can be used without particular limitation as long as the gene can be expressed in the target cell.
- an expression cassette capable of expressing a gene in animal-derived cells more preferably, an expression cassette capable of expressing a gene in mammalian cells, and particularly preferably, a human-derived expression cassette.
- Gene promoters used for expression sets include, for example, adenovirus, cytomegalovirus, human immunodeficiency (HIV) virus, simian virus 40, rous sarcoma virus, simple herpes virus, mouse leukemia virus, simvis virus, Sendai virus Promoters derived from viruses such as virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, norovirus, human T-cell leukemia virus, influenza virus, Japanese encephalitis virus, JC virus, parvovirus B19, and poliovirus And mammalian-derived promoters such as albumin heat shock protein, and chimeric promoters such as CAG Promoter.
- viruses such as virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, norovirus, human T-cell leukemia virus, influenza virus, Japanese encephalitis virus, JC virus, parvovirus B19, and poliovirus And mammalian-
- the nucleic acid carrier of the present invention is characterized by containing the polypeptide comprising the diaminobutyric acid and / or a pharmaceutically acceptable salt thereof, and the recombinant virus vector.
- a predetermined ratio of the polypeptide and the recombinant virus vector are combined, a complex is easily formed, and becomes the nucleic acid carrier of the present invention.
- one recombinant viral vector of the present invention already contains a suitable drug gene as indicated above.
- the recombinant virus vector and the plasmid according to the present invention By combining the peptides, a nucleic acid carrier that can be used for gene therapy and a composition for gene therapy can be obtained.
- a gene therapy composition is prepared by mixing the recombinant virus vector containing the drug gene with the polypeptide comprising diaminobutyric acid and Z or a pharmaceutically acceptable salt thereof.
- the gene therapy composition thus obtained is also included in the scope of the present invention.
- a polypeptide comprising diaminobutyric acid and / or a pharmaceutically acceptable salt thereof, and a recombinant virus vector containing a drug gene are each dissolved in water, physiological saline, isotonic buffer, etc. After dissolving in a suitable solvent and mixing, a composition for gene therapy can be prepared.
- the mixing ratio of the recombinant virus vector containing the drug gene and the polypeptide of the present invention to be used is not particularly limited.
- the polypeptide of the present invention is used at a concentration of 5 / zgZml to 20 zg / ml, preferably 5 gZml to 10 gZml.
- IU infectious units indicates the gene transfer efficiency (titer) of the recombinant virus vector, and means the number of cells into which the gene can be introduced with 1 ml of the virus vector solution.
- the gene transfer efficiency is determined, for example, by performing gene transfer treatment on any cell with a recombinant virus vector containing a neomycin drug resistance gene, and then culturing it in a culture solution containing the drug. Obtained by counting.
- the nucleic acid carrier of the present invention has formed a complex already 1 minute after mixing the polypeptide and the recombinant virus vector, and this complex is stable even after 1 hour from the formation. Present in the mixing solution.
- the nucleic acid carrier of the present invention does not cause precipitation even after mixing and complex formation. Therefore, there is no risk of causing a thrombus even if the nucleic acid carrier of the present invention is directly administered to blood vessels, It is possible to efficiently and safely administer drug genes.
- the nucleic acid carrier of the present invention can further contain an additive, if necessary.
- the peptide of the present invention is used to promote adsorption to cells, stabilize a recombinant virus vector, promote the introduction of drug genes into cells or nuclei, or control the release of recombinant virus vectors.
- Additives can be added as needed.
- Such additives are not particularly limited as long as they achieve the above-mentioned purpose, but are not particularly limited.
- the nucleic acid carrier of the present invention makes it possible to introduce and express a drug gene into a target cell more than three times more efficiently than introducing a drug gene with a single recombinant virus vector.
- the nucleic acid carrier of the present invention can be used for autologous gene therapy (ex vivo gene therapy) in which target cells are first taken out of a patient, a drug gene is introduced, and then the cells are returned to the patient. is there. It can also be used for gene therapy in which drug genes are directly administered to patients (in vivo gene therapy).
- Methods of gene therapy can be broadly classified into a method of adding a new (normal) gene while leaving the abnormal (cause) gene intact (Augumentation Gene Therapy) and a method of replacing the abnormal gene with a normal gene (Replacement Gene Therapy).
- the nucleic acid carrier of the present invention can be used for any of them.
- the method for administering the nucleic acid carrier of the present invention to a living body is not particularly limited.
- it can be preferably carried out by parenteral administration or injection administration.
- the dose of the nucleic acid carrier of the present invention varies depending on the method of use, the purpose of use, and the like, and those skilled in the art can easily and appropriately determine the optimal dose for the subject to be treated. is there.
- a daily dose of about 0.1 g / kg 100 mg / kg, and more preferably a daily dose of about 100 g / kg. 110 O mg / kg.
- poly- (2,4-diajninobutyric acid) is abbreviated as PDBA, including its acetate, and PDBA includes those based on all possible optical isomers.
- block copolymer with polyethylene glycol is also abbreviated as PDBApeg (or PDBA-PEG).
- DL-2,4-Diaminobutyric acid dihydrochloride (DL-2,4-diamino-n-butyric acid dihydrochloride) (1) Dissolve 15 g (manufactured by Sigma) in 75 ml of water. After adding 11.7 g of copper (2) and standing, the mixture was boiled under reflux and filtered. To the filtrate, 16.6 g of sodium hydrogencarbonate and 17.8 ml of carbobenzoxycyclolide (4) (manufactured by Wako Pure Chemical Industries, Ltd.) were added and stirred to obtain a product as a precipitate.
- N-carbobenzoxy-D-resaminobutyric acid copper complex (4N-carbobenzoxy-DL-2, 4-diaminobutyric acid copper complex; hereinafter referred to as Dba (Z) -Cu) ( 5) was obtained.
- Polypeptides composed of diaminobutyric acids having various numbers of residues are obtained by degenerating the obtained N-carbobenzoxy-DL-diaminobutyric acid NCA (10) using various ratios of initiators, It was obtained by removing the protecting group of the amino group.
- the molecular weight in the present invention means that represented by the following formula.
- EGFP EGFP Protein
- HIV-LTR HIV-LTR
- the gene construct expression downy Kuta containing the replication initiation point of the ampicillin resistance gene and SV40 - were co-transfected full Ekushi Yon into COS cells by the calcium phosphate method with the vector one was ⁇ the plasmid PHXCAGEGFP ( Figure 4). After culturing for 2 days, the obtained culture supernatant was centrifuged at 2000 rpm for 10 minutes, and the precipitate was removed to obtain a GFP / HIV vector solution.
- the GFP / HIV vector prepared in Production Example 2 and the PDBA solution prepared at twice the desired concentration were mixed in equal amounts immediately before administration, and the GFP / HIV vector, the nucleic acid carrier of the present invention, was mixed.
- a / PDBA complex solution was prepared.
- the final concentrations of PDBA were adjusted to be 0, 0.3, 1.0, 3.0, 5.0, 10.0, 15.0, 20.0, 25.0 g / ml, respectively.
- the solvent used was DMEM medium (Sigma).
- PDBA having a molecular weight of 7800 obtained in Synthesis Example 3 in Table 2 was used.
- PDBA having a molecular weight of 7800 obtained in Synthesis Example 3 in Table 2 was used.
- Test Example 1 Gene transfer into HeLa cells by GFP / HIV vector-1 / PDBA complex
- HeLa cells were placed on a 12-well multiwell plate (Coaster). 5 seeds were seeded per 1 well.
- a GFP / HIV vector / PDBA complex solution was administered in the presence of 10% fetal fetus serum (manufactured by Sanko Junyaku Co., Ltd.), and incubated at 37 ° C. for 4 hours. After replacing with a fresh culture solution, the cells were incubated for another 48 hours.
- FIG. 5 shows the ratio of cells into which the marker gene (EGFP) was introduced in 10,000 cells. It was confirmed that about 30% of cells were transfected with only one recombinant HIV vector (PDBA 0 ⁇ g / ml) used as a control.
- PDBA 0 ⁇ g / ml recombinant HIV vector
- the GFP / HIV vector prepared in Production Example 2 and the PDBA solution prepared at 20.0 g / ml were mixed in equal amounts 60, 30, 15, 10, 3, and 1 minute before the test to obtain a GFP / HIV vector.
- An HIV vector / PDBA complex solution (final concentration of PDBA was 10.0 ug / ml) was prepared.
- the solvent used was DEM medium (Sigma).
- PDBA having a molecular weight of 7,800, obtained by Synthesis Example 3 in Table 2, was used.
- Each GFP / HIV vector-1 / PDBA complex solution was allowed to stand at room temperature and then administered to HeLa cells. 48 hours later, the cells were fixed, and the gene transfer efficiency was measured using a flow cytometer overnight (FACS Cal ibur; manufactured by Becton Dickinson).
- FIG. 6 shows the percentage of cells into which the EGFP gene was introduced among 10,000 cells. From FIG. 6, it was confirmed that the PDBA and the recombinant virus vector immediately formed a stable complex after mixing, and that there was no change in the gene transfer efficiency even when left at room temperature for 1 hour. still, As in FIG. 5, the unit of the vertical axis in FIG. 6 is%, and the graph shows the gene transfer rate at each concentration in%, with the control being 100%.
- the nucleic acid carrier of the present invention forms a complex between a polypeptide comprising diaminobutyric acid and Z or a pharmaceutically acceptable salt thereof and a recombinant virus vector, and efficiently and safely transmits a drug gene to cells.
- the gene can be introduced, and high gene expression in the cells is guaranteed, which is useful for gene therapy.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00969954A EP1229124A4 (en) | 1999-10-20 | 2000-10-20 | NUCLEIC ACID CONVEYOR CONTAINING POLYPEPTIDE AND RECOMBINANT VIRAL VECTOR |
AU79526/00A AU7952600A (en) | 1999-10-20 | 2000-10-20 | Nucleic acid transporter containing polypeptide and recombinant virus vector |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29843399A JP2001120268A (ja) | 1999-10-20 | 1999-10-20 | ポリペプチドおよび組換えウイルスベクターを含む核酸運搬体 |
JP11/298433 | 1999-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001029244A1 true WO2001029244A1 (fr) | 2001-04-26 |
Family
ID=17859654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007337 WO2001029244A1 (fr) | 1999-10-20 | 2000-10-20 | Transporteur d'acide nucleique contenant un polypeptide et un vecteur viral de recombinaison |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1229124A4 (ja) |
JP (1) | JP2001120268A (ja) |
CN (1) | CN1164756C (ja) |
AU (1) | AU7952600A (ja) |
WO (1) | WO2001029244A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4535229B2 (ja) | 2003-05-08 | 2010-09-01 | 国立大学法人 東京大学 | ポリエチレングリコール−ポリカチオンブロック共重合体 |
CN102086266B (zh) * | 2010-12-24 | 2013-04-10 | 华东理工大学 | 含聚肽不对称超支化两性聚电解质及其制备方法 |
CN102199674A (zh) * | 2011-03-17 | 2011-09-28 | 中国疾病预防控制中心病毒病预防控制所 | 一种有包膜rna病毒核酸检测参照品/标准品平台及其应用方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0834572A3 (en) * | 1996-10-02 | 1999-08-25 | F. Hoffmann-La Roche Ag | Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives |
-
1999
- 1999-10-20 JP JP29843399A patent/JP2001120268A/ja active Pending
-
2000
- 2000-10-20 EP EP00969954A patent/EP1229124A4/en not_active Withdrawn
- 2000-10-20 WO PCT/JP2000/007337 patent/WO2001029244A1/ja not_active Application Discontinuation
- 2000-10-20 CN CNB008145326A patent/CN1164756C/zh not_active Expired - Fee Related
- 2000-10-20 AU AU79526/00A patent/AU7952600A/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
C.P. HODGSON ET AL.: "Virosomes: Cationic liposomes enhance retroviral transduction", NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 339 - 342, XP002936577 * |
D.T. CURIEL ET AL.: "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery", PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 8850 - 8854, XP002936578 * |
See also references of EP1229124A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001120268A (ja) | 2001-05-08 |
CN1164756C (zh) | 2004-09-01 |
EP1229124A4 (en) | 2002-12-04 |
AU7952600A (en) | 2001-04-30 |
CN1379821A (zh) | 2002-11-13 |
EP1229124A1 (en) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Naldini et al. | Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. | |
JP2006517916A (ja) | Rna干渉物質を用いてアポトーシス関連疾患を治療および予防する方法 | |
US20080124308A1 (en) | Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins | |
JP2024020452A (ja) | 遺伝子治療のためのポリマーカプセル化されたウイルスベクター | |
WO2001029244A1 (fr) | Transporteur d'acide nucleique contenant un polypeptide et un vecteur viral de recombinaison | |
AU749059B2 (en) | Therapeutic use of lentiviral vectors | |
Devitt et al. | Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine | |
US20220403416A1 (en) | Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy | |
JP2000210079A (ja) | 核酸運搬体及び遺伝子治療用薬物 | |
US20030148929A1 (en) | Nucleic acid carriers and pharmaceutical compositions for gene therapy | |
US20230120141A1 (en) | Polyethylene Glycol Conjugates of Polyethyleneimine and Their Use in Gene Therapy | |
AU765127B2 (en) | Nucleic acid transporters and medicinal compositions for gene therapy | |
JP2008195683A (ja) | 遺伝子導入剤 | |
JP5944622B2 (ja) | 遺伝子導入剤組成物 | |
Anderson et al. | 409. In Vivo Comparison of Liver-Specific Enhancer-Promoter Constructs in the Context of Lentiviral Vectors | |
US20040005708A1 (en) | Polypeptide derivatives and nucleic acid carriers containing the same | |
JP2007230896A (ja) | 遺伝子導入剤 | |
JP2004331562A (ja) | Il−12遺伝子を含む遺伝子治療用組成物 | |
JP2003501066A (ja) | Sivベースのパッケージング欠損ベクター | |
JP2007124956A (ja) | 遺伝子ベクター | |
WO2007052689A1 (ja) | 遺伝子導入剤及び遺伝子ベクター | |
JPH11322794A (ja) | ペプチド、核酸、組換えベクター、形質転換体、ペプチドの製造方法及び抗ウイルス性疾患剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 008145326 Country of ref document: CN Ref document number: 10111052 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000969954 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000969954 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000969954 Country of ref document: EP |